In this respect, targeting VEGF164 binding to NRP1 might have similar effects as treatment with Macugen, an aptamer that specifically targets VEGF164 and has been approved by the FDA for the treatment of AMD, even though its clinical use has been superseded by anti-VEGFs that target all isoforms (Ip et al., 2008, Rosenfeld, 2006). The gene discussed is NRP1; the disease is age-related macular degeneration.